Breaking News
Sort by:
Top Post
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today […]
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces […]
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
Avacta Provides Update on AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
Avacta Announces AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful […]
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Read more
- Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Read more
- Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Read more
- Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Read more
- Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Read more